Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). In addition to the chat, Theravance Biopharma's senior management team will be available for one-on-one meetings with investors during the conference.

Interested parties can access the webcast or schedule meetings with the management team by contacting their BTIG representative or emailing uscorporateaccess@btig.com. This event provides an opportunity for investors to gain insights into Theravance Biopharma's current activities and future plans directly from the company's leadership.

DUBLIN, July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To listen to the webcast or schedule meetings with management, please contact your BTIG representative or email uscorporateaccess@btig.com.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302206234.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) participating in the BTIG Virtual Biotechnology Conference?

Theravance Biopharma (TBPH) is participating in the BTIG Virtual Biotechnology Conference on Tuesday, August 6, with a fireside chat scheduled for 12:00 pm ET (9:00 am PT/5:00 pm IST).

What type of investor engagement is Theravance Biopharma (TBPH) offering at the BTIG conference?

Theravance Biopharma (TBPH) is offering a fireside chat and one-on-one meetings with senior management at the BTIG Virtual Biotechnology Conference.

How can investors access the webcast or schedule meetings with Theravance Biopharma (TBPH) management?

Investors can access the webcast or schedule meetings with Theravance Biopharma (TBPH) management by contacting their BTIG representative or emailing uscorporateaccess@btig.com.

What is the significance of Theravance Biopharma's (TBPH) participation in the BTIG conference?

Theravance Biopharma's (TBPH) participation in the BTIG conference provides an opportunity for investors to gain insights into the company's activities and plans directly from senior management, potentially impacting investor sentiment and stock performance.